CervoMed Publishes Phase 2b DLB Data; Primary Endpoint Missed in Full Population
CRVO is trading near its 52-week low of $1.66 (5.4% above the low) on elevated volume (3.9× avg).
Summary
CervoMed's Phase 2b DLB trial results are now peer-reviewed and published, confirming the drug missed its primary endpoint in the full population while showing benefit in patients without Alzheimer's co-pathology and in those with adequate drug exposure. The company still needs a partner to fund Phase 3.
Key Events · Product Development and Regulatory · CRVO
-
Phase 2b Results Peer-Reviewed
Alzheimer's Research & Therapy published the placebo-controlled phase of the 159-patient RewinD-LB trial of neflamapimod 40 mg three times daily in dementia with Lewy bodies.
-
Primary Endpoint Missed in Full Population
Neflamapimod did not confirm the Phase 2a CDR-SB result in the full intention-to-treat population; benefit appeared only in subgroups.
-
Subgroup Benefit, Confidence Intervals Cross Zero
Placebo-adjusted CDR-SB differences were -0.51 points (95% CI -1.16 to 0.13) at pTau181 <23 pg/mL and -0.70 points (95% CI -1.42 to 0.01) below 21 pg/mL; patients above the 3.64 ng/mL median drug level showed Phase 2a-comparable effects.
-
Exposure Threshold Supports New Tablet Dose
The publications identify a trough plasma concentration threshold of roughly 4 ng/mL for activity; the 100 mg twice-daily tablet is projected to reach target trough levels in more than 90% of participants.
Analysis · CRVO · Life Sciences
The peer-reviewed paper now puts the RewinD-LB results on the record: neflamapimod failed to confirm the Phase 2a CDR-SB benefit across the full 159-patient intention-to-treat group. That leaves the bull case resting entirely on the subgroups — patients without Alzheimer's co-pathology (placebo-adjusted -0.51 points at pTau181 <23 pg/mL, 95% CI -1.16 to 0.13) and patients above the 3.64 ng/mL median drug level — plus the MRI basal forebrain finding. Because those confidence intervals still cross zero, the data support a better-exposure 100 mg twice-daily tablet retest rather than proving efficacy. With a going-concern warning on the books and no partner signed, the company needs a strategic partner to fund Phase 3; a publication alone does not provide that.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CRVO was trading at $1.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $26.5M. The 52-week trading range was $1.66 to $10.00. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.